Clinical value and application of SPINK1 as a tumor biomarker

doi:10.3760/cma.j.cn371439-20200216-00047

Abstract

Abstract:

The serine protease inhibitor Kazal type 1 (SPINK1) is a member of the protease inhibitor family. As SPINK1 plays an essential role in the occurrence, development and prognosis of tumors, such as ovarian cancer,pancreatic cancer, hepatocellular carcinoma, colorectal cancer and prostate cancer, the clinical application of SPINK1 as a tumor marker has been widely concerned by researchers.

Key words: Serine protease inhibitors, Biomarkers, Neoplasms, Prognosis

Zhao Na, Zheng Yang, Chen Lili, Jing Donghui, Wang Huaqing. Clinical value and application of SPINK1 as a tumor biomarker[J]. Journal of International Oncology, 2020, 47(7): 414-418.

References 42

[1]	Itkonen O, Stenman UH. TATI as a biomarker[J]. Clin Chim Acta, 2014,431:260-269. DOI: 10.1016/j.cca.2014.02.014. doi: 10.1016/j.cca.2014.02.014 pmid: 24583226
[2]	Huhtala ML, Pesonen K, Kalkkinen N, et al. Purification and characterization of a tumor-associated trypsin inhibitor from the urine of a patient with ovarian cancer[J]. J Biol Chem, 1982,257(22):13713-13716. pmid: 7142173
[3]	Räsänen K, Itkonen O, Koistinen H, et al. Emerging roles of SPINK1 in cancer[J]. Clin Chem, 2016,62(3):449-457. DOI: 10.1373/clinchem.2015.241513. doi: 10.1373/clinchem.2015.241513 pmid: 26656134
[4]	Mehner C, Radisky ES. Bad tumors made worse: SPINK1[J]. Front Cell Dev Biol, 2019,7:10. DOI: 10.3389/fcell.2019.00010. doi: 10.3389/fcell.2019.00010 pmid: 30778387
[5]	Bonifácio VDB. Ovarian cancer biomarkers: moving forward in early detection[J]. Adv Exp Med Biol, 2020,1219:355-363. DOI: 10.1007/978-3-030-34025-4_18. doi: 10.1007/978-3-030-34025-4_18 pmid: 32130708
[6]	Nissi R, Talvensaari-Mattila A, Kuvaja P, et al. Claudin-5 is asso-ciated with elevated TATI and CA125 levels in mucinous ovarian borderline tumors[J]. Anticancer Res, 2015,35(2):973-976. pmid: 25667483
[7]	Mehner C, Oberg AL, Kalli KR, et al. Serine protease inhibitor Kazal type 1 (SPINK1) drives proliferation and anoikis resistance in a subset of ovarian cancers[J]. Oncotarget, 2015,6(34):35737-35754. DOI: 10.18632/oncotarget.5927. doi: 10.18632/oncotarget.5927 pmid: 26437224
[8]	Shadhu K, Xi C. Inflammation and pancreatic cancer: an updated review[J]. Saudi J Gastroenterol, 2019,25(1):3-13. DOI: 10.4103/sjg.SJG_390_18. doi: 10.4103/sjg.SJG_390_18 pmid: 30588953
[9]	Muller N, Sarantitis I, Rouanet M, et al. Natural history of SPINK1 germline mutation related-pancreatitis[J]. EBioMedicine, 2019,48:581-591. DOI: 10.1016/j.ebiom.2019.09.032. doi: 10.1016/j.ebiom.2019.09.032 pmid: 31628023
[10]	张敏, 王银萍, 倪劲松, 等. CFTR及SPINK1蛋白在慢性胰腺炎及胰腺癌中的表达及其意义[J]. 中国实验诊断学, 2011,15(10):1625-1628. DOI: 10.3969/j.issn.1007-4287.2011.10.005.
[11]	Zhang J, Wang D, Hu N, et al. The construction and proliferative effects of a lentiviral vector capable of stably overexpressing SPINK1 gene in human pancreatic cancer AsPC-1 cell line[J]. Tumour Biol, 2016,37(5):5847-5855. DOI: 10.1007/s13277-015-4405-z. pmid: 26586397
[12]	Johnson MH, Ross AE, Alshalalfa M, et al. SPINK1 defines a molecular subtype of prostate cancer in men with more rapid progression in an at risk, natural history radical prostatectomy cohort[J]. J Urol, 2016,196(5):1436-1444. DOI: 10.1016/j.juro.2016.05.092. doi: 10.1016/j.juro.2016.05.092 pmid: 27238617
[13]	Yun SJ, Kim SK, Kim J, et al. Transcriptomic features of primary prostate cancer and their prognostic relevance to castration-resistant prostate cancer[J]. Oncotarget, 2017,8(70):114845-114855. DOI: 10.18632/oncotarget.22296. pmid: 29383125
[14]	Zhang X, Yin X, Shen P, et al. The association between SPINK1 and clinical outcomes in patients with prostate cancer: a systematic review and meta-analysis[J]. Onco Targets Ther, 2017,10:3123-3130. DOI: 10.2147/OTT.S127317. pmid: 28790846
[15]	Wang C, Wang L, Su B, et al. Serine protease inhibitor Kazal type 1 promotes epithelial-mesenchymal transition through EGFR signaling pathway in prostate cancer[J]. Prostate, 2014,74(7):689-701. DOI: 10.1002/pros.22787. doi: 10.1002/pros.22787
[16]	徐圆圆, 张丽, 金良昆. 免疫微环境介导的肿瘤耐受机制及其靶向治疗[J]. 国际肿瘤学杂志, 2017,44(8):594-596. DOI: 10.3760/cma.j.issn.1673-422X.2017.08.009.
[17]	Chen F, Long Q, Fu D, et al. Targeting SPINK1 in the damaged tumour microenvironment alleviates therapeutic resistance[J]. Nat Commun, 2018,9(1):4315. DOI: 10.1038/s41467-018-06860-4. pmid: 30333494
[18]	Luo P, Wu S, Yu YL, et al. Current status and perspective biomarkers in AFP negative HCC: towards screening for and diagnosing hepatocellular carcinoma at an earlier stage[J]. Pathol Oncol Res, 2020,26(2):599-603. DOI: 10.1007/s12253-019-00585-5. doi: 10.1007/s12253-019-00585-5 pmid: 30661224
[19]	Jee BA, Choi JH, Rhee H, et al. Dynamics of genomic, epige-nomic, and transcriptomic aberrations during stepwise hepatocarcino-genesis[J]. Cancer Res, 2019,79(21):5500-5512. DOI: 10.1158/0008-5472.CAN-19-0991. doi: 10.1158/0008-5472.CAN-19-0991 pmid: 31506333
[20]	Huang K, Xie W, Wang S, et al. High SPINK1 expression predicts poor prognosis and promotes cell proliferation and metastasis of hepatocellular carcinoma[J]. J Invest Surg, 2020, 1-10. DOI: 10.1080/08941939.2020.1728443. doi: 10.1080/08941939.2020.1786612 pmid: 32619124
[21]	Shek FH, Luo R, Lam BYH, et al. Serine peptidase inhibitor Kazal type 1 (SPINK1) as novel downstream effector of the cadherin-17/β-catenin axis in hepatocellular carcinoma[J]. Cell Oncol (Dordr), 2017,40(5):443-456. DOI: 10.1007/s13402-017-0332-x.
[22]	Chang C, Zhao W, Luo Y, et al. Serine peptidase inhibitor Kazal type Ⅰ (SPINK1) promotes BRL-3A cell proliferation via p38, ERK, and JNK pathways[J]. Cell Biochem Funct, 2017,35(6):339-348. DOI: 10.1002/cbf.3288. pmid: 28845526
[23]	Ying HY, Gong CJ, Feng Y, et al. Serine protease inhibitor Kazal type 1 (SPINK1) downregulates E-cadherin and induces EMT of hepatoma cells to promote hepatocellular carcinoma metastasis via the MEK/ERK signaling pathway[J]. J Dig Dis, 2017,18(6):349-358. DOI: 10.1111/1751-2980.12486. pmid: 28544403
[24]	Li F, Liu T, Xiao CY, et al. FOXP1 and SPINK1 reflect the risk of cirrhosis progression to HCC with HBV infection[J]. Biomed Pharmacother, 2015,72:103-108. DOI: 10.1016/j.biopha.2015.04.006. pmid: 26054682
[25]	Zhu C, Han H, Li J, et al. Hepatitis B virus X protein-induced serine protease inhibitor Kazal type 1 is associated with the progression of HBV-related diseases[J]. Biomed Res Int, 2019,2019:9321494. DOI: 10.1155/2019/9321494. doi: 10.1155/2019/9321494 pmid: 31240230
[26]	El-mezayen HA, Metwally FM, Darwish H. A novel discriminant score based on tumor-associated trypsin inhibitor for accurate diag-nosis of metastasis in patients with breast cancer[J]. Tumour Biol, 2014,35(3):2759-2767. DOI: 10.1007/s13277-013-1366-y. pmid: 24222329
[27]	Soon WW, Miller LD, Black MA, et al. Combined genomic and phenotype screening reveals secretory factor SPINK1 as an invasion and survival factor associated with patient prognosis in breast cancer[J]. EMBO Mol Med, 2011,3(8):451-464. DOI: 10.1002/emmm.201100150. pmid: 21656687
[28]	Kapoor S. Diagnostic and prognostic value of tumor-associated trypsin inhibitor in gastrointestinal malignancies[J]. Scand J Gastroenterol, 2014,49(4):514-515. DOI: 10.3109/00365521.2013.878385. doi: 10.3109/00365521.2013.878385 pmid: 24444434
[29]	Koide H, Kimura T, Inaba H, et al. Comparison of ERG and SPINK1 expression among incidental and metastatic prostate cancer in Japanese men[J]. Prostate, 2019,79(1):3-8. DOI: 10.1002/pros.23705. pmid: 30051483
[30]	Koskensalo S, Louhimo J, Hagström J, et al. Concomitant tumor expression of EGFR and TATI/SPINK1 associates with better prog-nosis in colorectal cancer[J]. PLoS One, 2013,8(10):e76906. DOI: 10.1371/journal.pone.0076906. pmid: 24204699
[31]	Tan Z, Gao L, Wang Y, et al. PRSS contributes to cetuximab resis-tance in colorectal cancer[J]. Sci Adv, 2020, 6(1): eaax5576. DOI: 10.1126/sciadv.aax5576. doi: 10.1126/sciadv.aax5576 pmid: 31911942
[32]	Kasurinen A, Laitinen A, Kokkola A, et al. Tumor-associated trypsin inhibitor (TATI) and tumor-associated trypsin-2 (TAT-2) predict outcomes in gastric cancer[J]. Acta Oncol, 2020,59(6):681-688. DOI: 10.1080/0284186X.2020.1733655. doi: 10.1080/0284186X.2020.1733655
[33]	Rink M, Park K, Volkmer BG, et al. Loss of SPINK1 expression is associated with unfavorable outcomes in urothelial carcinoma of the bladder after radical cystectomy[J]. Urol Oncol, 2013,31(8):1716-1724. DOI: 10.1016/j.urolonc.2012.06.011. doi: 10.1016/j.urolonc.2012.06.011 pmid: 22944196
[34]	Jiang W, Zhu D, Wang C, et al. An immune relevant signature for predicting prognoses and immunotherapeutic responses in patients with muscle-invasive bladder cancer (MIBC)[J]. Cancer Med, 2020,9(8):2774-2790. DOI: 10.1002/cam4.2942. doi: 10.1002/cam4.2942 pmid: 32096345
[35]	Guo M, Zhou X, Han X, et al. SPINK1 is a prognosis predicting factor of non-small cell lung cancer and regulates redox homeostasis[J]. Oncol Lett, 2019,18(6):6899-6908. DOI: 10.3892/ol.2019.11005. doi: 10.3892/ol.2019.11005 pmid: 31788129
[36]	Xu L, Lu C, Huang Y, et al. SPINK1 promotes cell growth and metastasis of lung adenocarcinoma and acts as a novel prognostic biomarker[J]. BMB Rep, 2018,51(12):648-653. DOI: 10.5483/BMBRep.2018.51.12.205. pmid: 30545439
[37]	Kozakiewicz B, Chadzyńska M, Dmoch-Gajzlerska E, et al. Moni-toring the treatment outcome in endometrial cancer patients by CEA and TATI [J]. Tumor Biol, 2016,37(7):9367-9374. DOI: 10.1007/s13277-016-4784-9. doi: 10.1007/s13277-016-4784-9
[38]	Liu A, Xue Y, Liu F, et al. Prognostic value of the combined expression of tumor-associated trypsin inhibitor (TATI) and p53 in patients with bladder cancer undergoing radical cystectomy[J]. Cancer Biomark, 2019,26(3):281-289. DOI: 10.3233/CBM-182143. doi: 10.3233/CBM-182143 pmid: 31594208
[39]	Masfufa IW, Fattah M. The correlation between serum SPINK1 and CA 15-3[J]. Clin Chim Acta, 2019,493(2019):S118-S118. DOI: 10.1016/j.cca.2019.03.250.
[40]	Janeiro E, Guimarães J, Stenman UH, et al. Validation and comparison of tumor-associated trypsin inhibitor (TATI) immunoassays [J]. Clin Chim Acta, 2012,413(15-16):1244-1248. DOI: 10.1016/j.cca.2012.04.001. doi: 10.1016/j.cca.2012.04.001
[41]	Ravela S, Valmu L, Domanskyy M, et al. An immunocapture-LC-MS-based assay for serum SPINK1 allows simultaneous quantification and detection of SPINK1 variants[J]. Anal Bioanal Chem, 2018,410(6):1679-1688. DOI: 10.1007/s00216-017-0803-y. doi: 10.1007/s00216-017-0803-y pmid: 29318362
[42]	Faisal FA, Kaur HB, Tosoian JJ, et al. SPINK1 expression is enriched in African American prostate cancer but is not associated with altered immune infiltration or oncologic outcomes post-prostatectomy[J]. Prostate Cancer ProstaticDis, 2019,22(4):552-559. DOI: 10.1038/s41391-019-0139-0.